Cargando…
Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach
Numerous therapeutic options have been introduced for metastatic renal cell carcinoma (mrcc) in recent years, including monoclonal antibodies such as bevacizumab and small-molecule tyrosine kinase inhibitors such as sunitinib and sorafenib. Similarly, several other small-molecule inhibitors—includin...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Multimed Inc.
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669228/ https://www.ncbi.nlm.nih.gov/pubmed/19370179 |